259 related articles for article (PubMed ID: 23524863)
1. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Sandhu SK; Omlin A; Hylands L; Miranda S; Barber LJ; Riisnaes R; Reid AH; Attard G; Chen L; Kozarewa I; Gevensleben H; Campbell J; Fenwick K; Assiotis I; Olmos D; Yap TA; Fong P; Tunariu N; Koh D; Molife LR; Kaye S; Lord CJ; Ashworth A; de Bono J
Ann Oncol; 2013 May; 24(5):1416-8. PubMed ID: 23524863
[No Abstract] [Full Text] [Related]
2. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
[No Abstract] [Full Text] [Related]
5. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
6. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
Quigley D; Alumkal JJ; Wyatt AW; Kothari V; Foye A; Lloyd P; Aggarwal R; Kim W; Lu E; Schwartzman J; Beja K; Annala M; Das R; Diolaiti M; Pritchard C; Thomas G; Tomlins S; Knudsen K; Lord CJ; Ryan C; Youngren J; Beer TM; Ashworth A; Small EJ; Feng FY
Cancer Discov; 2017 Sep; 7(9):999-1005. PubMed ID: 28450426
[TBL] [Abstract][Full Text] [Related]
8. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
Helleday T
Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
[No Abstract] [Full Text] [Related]
10. Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
Copur MS; Gauchan D; Brussow K; Clark D; Ramaekers R
J Clin Oncol; 2015 Aug; 33(23):2582. PubMed ID: 26124479
[No Abstract] [Full Text] [Related]
11. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
12. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
13. Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.
Chedgy EC; Black PC
Urology; 2016 Mar; 89():10-1. PubMed ID: 26723184
[No Abstract] [Full Text] [Related]
14. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
15. Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study finds.
Mayor S
BMJ; 2015 Oct; 351():h5783. PubMed ID: 26518710
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
17. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification and repair defects: revealing hidden treasures.
Hutchinson L
Nat Rev Clin Oncol; 2015 Dec; 12(12):683. PubMed ID: 26573421
[No Abstract] [Full Text] [Related]
20. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
Saillant A; Flippot R
Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
[No Abstract] [Full Text] [Related]
[Next] [New Search]